Skip to main content Accessibility help
  • Print publication year: 2019
  • Online publication date: October 2019

Chapter 8 - Ischemic Stroke Etiology and Secondary Prevention


In this chapter, we discuss mainly secondary prevention for stroke, although many of the measures, especially control of risk factors and lifestyle changes such as not smoking, controlling blood pressure, etc., are also important measures to avoid a first stroke.

Initially, we discuss a tailored diagnostic work-up, then general measures for secondary prevention of ischemic stroke, and finally recommendations for specific conditions that are associated with a high risk of recurrent stroke.

1.Chobanian, AV, Bakris, GL, Black, HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 25602572.
2.SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 32553264.
3.Yusuf, S, Sleight, P, Pogue, J, et al.; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145153.
4.PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 10331041.
5.ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 29812997.
6.Dahlof, B, Devereux, RB, Kjeldsen, SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 9951003.
7.Psaty, BM, Lumley, T, Furberg, CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 25342544.
8.Whelton, PK, Carey, RM, Aronow, WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018; 138: e426e483. doi:10.1161/CIR.0000000000000597.
9.Wright, JT, Williamson, JD, Whelton, PK, et al. A randomized trial of intensive versus standard blood‐pressure control. N Engl J Med 2015; 373: 21032116.
10.Grundy, SM, Stone, NJ, Bailey, AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1046–e1081. doi:10.1161/CIR.0000000000000625.
11.Amarenco, P, Bogousslavsky, J, Callahan, A, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549559.
12.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 722.
13.Powers, WJ, Rabinstein, AA, Ackerson, T, et al.; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49: e46e110. doi:10.1161/STR.0000000000000158.
14.Bruno, A, Durkalski, VL, Hall, CE, et al. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial protocol: a randomized, blinded, efficacy trial of standard vs. intensive hyperglycemia management in acute stroke. Int J Stroke 2014; 9: 246251. doi:10.1111/ijs.12045.
15.Kernan, WN, Viscoli, CM, Furie, KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 374: 13211331. doi:10.1056/NEJMoa1506930.
16.Estruch, R, Ros, E, Salas-Salvadó, J, et al.; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 12791290. Corrected and republished in: N Engl J Med 2018; 378: e34.
17.Viscoli, CM, Brass, LM, Kernan, WN, et al. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 12431249.
18.Anderson, GL, Limacher, M, Assaf, AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291: 17011712.
19.Rossouw, JE, Anderson, GL, Prentice, RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321333.
20.Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81106.
21.Diener, HC, Cunha, L, Forbes, C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 113.
22.ESPS Group. The European Stroke Prevention Study (ESPS): principal end-points. Lancet 1987; 2: 13511354.
23.Sacco, RL, Diener, HC, Yusuf, S, et al.; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 12381251.
24.Johnston, SC, Amarenco, P, Albers, GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016; 375: 3543. doi:10.1056/NEJMoa1603060.
25.Amarenco, P, Albers, GW, Denison, H, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol 2017; 16: 301310. doi:10.1016/S1474-4422(17)30038-8.
26.Dinicolantonio, JJ, Lavie, CJ, Fares, H, et al. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol 2013; 112: 12301234. doi:10.1016/j.amjcard.2013.05.067.
27.Costa, J, Ferro, JM, Matias-Guiu, J, Álvarez-Sabín, J, Torres, F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005; (3): CD004296.
28.Chimowitz, MI, Lynn, MJ, Derdeyn, CP, et al.; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 9931003.
29.Wang, Y, Wang, Y, Zhao, X, et al.; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 1119. doi:10.1056/NEJMoa1215340.
30.Johnston, SC, Easton, JD, Farrant, M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379: 215225. doi:10.1056/NEJMoa1800410.
31.Benavente, OR, Hart, RG, McClure, LA, et al.; SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367: 817825. doi:10.1056/NEJMoa1204133.
32.Diener, HC, Bogousslavsky, J, Brass, LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331337.
33.Bhatt, DL, Fox, KA, Hacke, W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 17061717.
34.van Es, N, Coppens, M, Schulman, S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 19681975. doi:10.1182/blood-2014-04-571232.
35.Choe, WC, Passman, RS, Brachmann, J, et al. A comparison of atrial fibrillation monitoring strategies after cryptogenic stroke (from the Cryptogenic Stroke and Underlying AF Trial). Am J Cardiol 2015; 116: 889893. doi:10.1016/j.amjcard.2015.06.012.
36.Sanna, T, Diener, HC, Passman, RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370: 24782486.
37.Gladstone, DJ, Spring, M, Dorian, P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370: 24672477.
38.Reddy, VY, Doshi, SK, Kar, S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017; 70: 29642975. doi:10.1016/j.jacc.2017.10.021.
39.Barnett, HJ, Taylor, DW, Eliasziw, M, et al.; North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998; 339: 14151425.
40.Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 14211428.
41.Halliday, A, Mansfield, A, Marro, J, et al.; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363: 14911502.
42.Brott, TG, Hobson, RW, Howard, G, et al.; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 1123.
43.Rosenfield, K, Matsumura, JS, Chaturvedi, S, et al. Randomized trial of stent versus surgery for asymptomatic carotid stenosis. N Engl J Med 2016; 374: 10111020. doi:10.1056/NEJMoa1515706.
44.Rothwell, PM, Eliasziw, M, Gutnikov, SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363: 915924.
45.Rothwell, PM, Eliasziw, M, Gutnikov, SA, et al. Sex difference in the effect of time from symptoms to surgery on benefit from carotid endarterectomy for transient ischemic attack and nondisabling stroke. Stroke 2004; 35: 28552861.
46.Grubb, RL, Powers, WJ, Derdeyn, CP, et al. The carotid occlusion surgery study. Neurosurg Focus 2003; 14 (3): e9.
47.Chimowitz, MI, Lynn, MJ, Howlett-Smith, H, et al.; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 13051316.
48.Yonemura, K, Kimura, K, Minematsu, K, et al. Small centrum ovale infarcts on diffusion-weighted magnetic resonance imaging. Stroke 2002; 33: 15411544.
49.Vahidy, FS, Hicks, WJ, Acosta, I, et al. Neurofluctuation in patients with subcortical ischemic stroke. Neurology 2014; 83: 398405. doi:10.1212/WNL.0000000000000643.
50.Markus, HS, Hayter, E, Levi, C, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. CADISS trial investigators. Lancet Neurol 2015; 14: 361367. doi:10.1016/S1474-4422(15)70018-9. Erratum in: Lancet Neurol 2015; 14: 566.
51.Touze, E, Gauvrit, JY, Moulin, T, et al. Risk of stroke and recurrent dissection after a cervical artery dissection: a multicenter study. Neurology 2003; 61: 13471351.
52.Overell, JR, Bone, I, Lees, KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55: 11721179.
53.Mas, JL, Derumeaux, G, Guillon, B, et al.; CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017; 377: 10111021. doi:10.1056/NEJMoa1705915.
54.Saver, JL, Carroll, JD, Thaler, DE, et al.; RESPECT Investigators. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377: 10221032. doi:10.1056/NEJMoa1610057.
55.Søndergaard, L, Kasner, SE, Rhodes, JF, et al.; Gore REDUCE Clinical Study Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377: 10331042. doi:10.1056/NEJMoa1707404.